/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a licensing agreement with...
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Eyenovia, Inc. (Nasdaq: EYEN) concerning the Company and its directors’ and officers’ possible violations of state laws.
/PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into a collaboration agreement with...
Announced appointment of Michael Rowe as Chief Executive Officer and Board member Mydcombi™ NDA resubmission on track for the fourth quarter of 2022 ...
Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -28.57% and 34.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...
ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and...
New internal manufacturing capabilities to complement existing contract manufacturing relationships...
Arctic Vision also licensed and is developing Eyenovia’s programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in...